4D Molecular Therapeutics, Inc. (FDMT)
SEC fundamentals · as filed in 10-Q FY2026, period ended Jun 30, 2026 · updated Oct 7, 2026
as filed in 10-Q FY2026, period ended Jun 30, 2026 · View filings on EDGAR ↗
In its 10-Q for the period ended Jun 30, 2026, 4D Molecular Therapeutics, Inc. reported revenue of $3.8M, net income of -$72.9M, and total assets of $492.6M. Every figure below is taken directly from 4D Molecular Therapeutics, Inc.'s SEC filings: each links to the source document on EDGAR.
Revenue trend
Revenue · FY2019–FY2025 · as reported
- FY2019 revenue
- $7.0M
- FY2025 revenue
- $85.2M
Revenue and net income by fiscal year
As reported in each year’s annual filing · USD
| Fiscal year | Revenue | Net income |
|---|---|---|
| FY2025 | $85.2M | -$140.1M |
| FY2024 | $37,000 | -$160.9M |
| FY2023 | $20.7M | -$100.8M |
| FY2022 | $3.1M | -$107.5M |
| FY2021 | $18.0M | -$71.3M |
| FY2020 | $13.6M | -$56.7M |
| FY2019 | $7.0M | -$49.3M |
Recent SEC filings
Filed by the registrant · newest first · insider forms and holder schedules not included
| Form | Filed | Source |
|---|---|---|
| 8-K | Sep 28, 2026 | on EDGAR ↗ |
| 8-K | Aug 13, 2026 | on EDGAR ↗ |
| 10-Q | Aug 13, 2026 | on EDGAR ↗ |
| 8-K | Jul 20, 2026 | on EDGAR ↗ |
| 8-K | Jun 29, 2026 | on EDGAR ↗ |
| 8-K | Jun 22, 2026 | on EDGAR ↗ |
| 8-K | May 7, 2026 | on EDGAR ↗ |
| 10-Q | May 7, 2026 | on EDGAR ↗ |
| DEF 14A | Apr 28, 2026 | on EDGAR ↗ |
| 8-K | Mar 30, 2026 | on EDGAR ↗ |
Balance Sheet
as of Jun 30, 2026 · 10-Q
Income Statement
10-Q (quarterly) · period ended Jun 30, 2026
Per Share & Cash Flow
10-Q (quarterly) · period ended Jun 30, 2026
| EPS (diluted) | $-1.04 | Earnings | source ↗ |
| EPS (basic) | $-1.04 | Earnings | source ↗ |
| Shares Outstanding | 55.2M | Common | source ↗ |
| Cash from Operations | -$70.0M | Net | source ↗ |
| Cash from Financing | $42.3M | Net | source ↗ |
| Cash from Investing | $25.5M | Net | source ↗ |
Insider activity
Form 4 open-market activity, last 180 days
- Buys
- 0
- Sells
- 19
- Net shares
- -423.5K
Restatement history
Point-in-timeNo material restatements detected across 155 annual fact-keys: this company's as-filed numbers have held between filings. Point-in-time and as-of history are available via the API.
Deeper fundamentals
A free API key reaches FDMT’s revenue, margin and free-cash-flow trajectory (newest 3 fiscal years) and its leverage, liquidity and return ratios (newest 4 quarters). Analyst extends those to up to 20 years and 20 quarters, and adds the Piotroski F-score and accruals quality score. As-of fundamentals at any past date are on Free too, up to 10 lookups a day; Analyst removes that cap and adds the original-vs-restated detail, across the whole SEC universe.
Programmatic access
Everything on this page is served by the Distill API and by the MCP server at mcp.distillmarkets.com. A free key is issued at sign-up with no card; the full reference is in the docs.
- These fundamentals, as filed
- curlcurl -H "X-Api-Key: $DISTILL_API_KEY" \https://api.distillmarkets.com/api/v1/sec/fundamentals/FDMT
MCP tool:
get_sec_fundamentals ticker=FDMT - The same figures as they were known on any past date
- curlcurl -H "X-Api-Key: $DISTILL_API_KEY" \https://api.distillmarkets.com/api/v1/sec/fundamentals/FDMT/as-of/YYYY-MM-DD
MCP tool:
get_asof_fundamentals ticker=FDMT as_of=YYYY-MM-DD - Fiscal-year trajectory: revenue, margins, free cash flow
- curlcurl -H "X-Api-Key: $DISTILL_API_KEY" \https://api.distillmarkets.com/api/v1/sec/fundamentals/FDMT/history
MCP tool:
get_fundamentals_history ticker=FDMT - Leverage, liquidity, margin and return ratios
- curlcurl -H "X-Api-Key: $DISTILL_API_KEY" \https://api.distillmarkets.com/api/v1/sec/financial-health/FDMT
MCP tool:
get_financial_health ticker=FDMT
Not investment advice. Figures are shown as filed with the SEC; see the EDGAR source links for the original documents. Data may lag the latest filing.